Epidemiology and factors associated with peripheral neuropathy among HIV infected patients in Gondar, Ethiopia: A cross-sectional study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
10
2018
accepted:
13
01
2019
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Antiretroviral therapy has surely increased the life expectancy of people living with HIV. However, long term complications like HIV associated sensory neuropathy has a negative impact on quality of life among people living with HIV (PLHIV). In Ethiopia, lack of data on magnitude of the burden and predictors of HIV associated sensory neuropathy in many resource limited setting has led to under diagnosis and eventually under management of HIV-SN. Hence, this study was set out to establish the burden of HIV-associated sensory neuropathy and, its association with demographic, health and clinical characteristics among people living with HIV in Ethiopia. Cross-sectional study was conducted to assess the prevalence of HIV-associated sensory neuropathy and the associated factors among adult HIV patients at University of Gondar Teaching Hospital, Gondar, Ethiopia. Brief Peripheral Neuropathy Screening tool validated by AIDs Clinical trial group was used for screening HIV-associated sensory neuropathy. Data were analyzed descriptively and through uni- and multivariate logistic regression. In total 359 adult PLHIV with a mean age of 36.5± 9.07 years participated, their median duration of HIV infection was 60 months (IQR 36-84) and their median CD4 count 143cells/μL (IQR 69.5-201.5). Age above 40 years, anti-tuberculosis regimen, tallness, and exposure to didanosine contained antiretroviral therapy were found to be associated with HIV-associated sensory neuropathy (AOR 1.82, 1.84, 1.98 and 4.33 respectively). More than half of the HIV patients who attended HIV care clinic at University of Gondar hospital during the study period were found to present with peripheral sensory neuropathy. Higher age, tallness, TB medication, and didanosine in ART were significantly associated with HIV-SN as screened by effective diagnostic (BPNS) tool.
Sections du résumé
BACKGROUND
Antiretroviral therapy has surely increased the life expectancy of people living with HIV. However, long term complications like HIV associated sensory neuropathy has a negative impact on quality of life among people living with HIV (PLHIV). In Ethiopia, lack of data on magnitude of the burden and predictors of HIV associated sensory neuropathy in many resource limited setting has led to under diagnosis and eventually under management of HIV-SN. Hence, this study was set out to establish the burden of HIV-associated sensory neuropathy and, its association with demographic, health and clinical characteristics among people living with HIV in Ethiopia.
METHODS
Cross-sectional study was conducted to assess the prevalence of HIV-associated sensory neuropathy and the associated factors among adult HIV patients at University of Gondar Teaching Hospital, Gondar, Ethiopia. Brief Peripheral Neuropathy Screening tool validated by AIDs Clinical trial group was used for screening HIV-associated sensory neuropathy. Data were analyzed descriptively and through uni- and multivariate logistic regression.
RESULTS
In total 359 adult PLHIV with a mean age of 36.5± 9.07 years participated, their median duration of HIV infection was 60 months (IQR 36-84) and their median CD4 count 143cells/μL (IQR 69.5-201.5). Age above 40 years, anti-tuberculosis regimen, tallness, and exposure to didanosine contained antiretroviral therapy were found to be associated with HIV-associated sensory neuropathy (AOR 1.82, 1.84, 1.98 and 4.33 respectively).
CONCLUSIONS
More than half of the HIV patients who attended HIV care clinic at University of Gondar hospital during the study period were found to present with peripheral sensory neuropathy. Higher age, tallness, TB medication, and didanosine in ART were significantly associated with HIV-SN as screened by effective diagnostic (BPNS) tool.
Identifiants
pubmed: 30695060
doi: 10.1371/journal.pone.0211354
pii: PONE-D-18-30305
pmc: PMC6350981
doi:
Substances chimiques
Didanosine
K3GDH6OH08
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211354Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2005 Jan 1;40(1):148-57
pubmed: 15614705
J Neurovirol. 2016 Feb;22(1):104-13
pubmed: 26323809
J Neurovirol. 2012 Oct;18(5):428-33
pubmed: 22806348
AIDS Read. 2005 Jul;15(7):341-4, 348-9, 354
pubmed: 16044575
AIDS. 2008 Jan 2;22(1):67-74
pubmed: 18090393
Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):247-55
pubmed: 20066675
Neurology. 2017 Aug 1;89(5):485-491
pubmed: 28679596
BMC Infect Dis. 2011 Sep 17;11:244
pubmed: 21923929
AIDS. 2011 Apr 24;25(7):919-28
pubmed: 21330902
Neurology. 2009 Jul 28;73(4):315-20
pubmed: 19636052
Int J STD AIDS. 2006 Jul;17(7):467-72
pubmed: 16820077
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10
pubmed: 17414931
J Neuroimmune Pharmacol. 2011 Dec;6(4):477-89
pubmed: 21755286
Trop Med Int Health. 2011 Oct;16(10):1291-6
pubmed: 21707880
Am J Trop Med Hyg. 2010 Sep;83(3):565-70
pubmed: 20810821
Curr Pain Headache Rep. 2012 Jun;16(3):226-36
pubmed: 22367397
Addict Sci Clin Pract. 2017 Jan 6;12(1):3
pubmed: 28057079
Stat Med. 2005 Apr 30;24(8):1245-61
pubmed: 15580592
J Pain Symptom Manage. 2011 Apr;41(4):700-6
pubmed: 21145196
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
Ann Neurol. 2006 May;59(5):816-24
pubmed: 16634006
Ann Intern Med. 2010 Jan 19;152(2):85-92
pubmed: 20083827
SAHARA J. 2012;9(2):88-94
pubmed: 23237043
J Neurosci Nurs. 2013 Feb;45(1):5-13
pubmed: 23291867
Neurology. 2008 Jun 10;70(24):2305-13
pubmed: 18541884
Neurology. 2005 Dec 13;65(11):1778-81
pubmed: 16344522
AIDS Res Ther. 2012 Nov 26;9(1):35
pubmed: 23181417
J Neurovirol. 2013 Dec;19(6):557-64
pubmed: 24297499
Ethiop Med J. 2010 Apr;48(2):85-93
pubmed: 20608012
J Diabetes Metab Disord. 2017 Apr 4;16:16
pubmed: 28396852
PLoS One. 2015 Jul 06;10(7):e0131353
pubmed: 26147987
AIDS Res Treat. 2012;2012:961510
pubmed: 22570772